News

reMYND signs license with BioPredic

10-01-2009
reMYND signs a license with BioPredic for commercialization RadarScreen as a diagnostic kit for experimental use in Europe and Japan. Visit the BioPredic website

reMYND receives a grant of almost 1 million EUR from IWT

10-12-2008
reMYND receives a grant of almost 1 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). Visit the IWT website

reMYND's Lead Alzheimer drug demonstrates neuroprotection

15-11-2008
reMYND's Lead Alzheimer drug demonstrates neuroprotection in 2 transgenic animal models of TAU and Amyloid bèta pathology.

reMYND licenses highly innovative transgenic mouse models

20-08-2008
reMYND licenses highly innovative transgenic mouse models of Alzheimer's Disease TAU and Amyloid pathology from the University of Leuven. Visit the University of Leuven website

reMYND installs world-class scientific advisory board

25-06-2008
reMYND installs world-class scientific advisory board with Parkinson's and Alzheimer's Disease experts.

Pages